Page 2 - Recursion Pharmaceuticals News Today

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price fell 5.5% during trading on Wednesday . The stock traded as low as $8.45 and last traded at $8.50. 1,189,638 shares changed hands during trading, a decline of 81% from the average session volume of 6,164,144 shares. The stock had previously closed at $8.99. Wall […]

Humacyte (NASDAQ:HUMA – Get Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Insider and Institutional Ownership 44.7% of Humacyte shares are […]

Recursion Pharmaceuticals, Inc. announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of the company, effective at the end of this term, as Martin Chavez exits...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "terrific spec"

Investegate announcements from Scottish Mortgage Inv Tst Final Result replacement

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the sale, the chief executive officer now owns 863,524 shares […]

The top performing exchange-traded fund is the CI Galaxy Blockchain Index ETF

The $50 million purchase could turn into Nvidia's biggest investment.

/PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the...